Effects of progesterone and anti-progestin (mifepristone) treatment on proliferation and apoptosis of the human ovarian cancer cell line, OVCAR-3

Oncology Reports

Volumn 15, Issue 4, 2006, Pages 743-748

  Fauvet, Raffaèle ^a,b   Etienne, Charlotte Dufournet ^a   Poncelet, Christophe ^b   Bringuier, Annie France ^b   Feldmann, Gérard ^b   Daraï, Emile ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

Anti progestin; Apoptosis; Culture cell; OVCAR 3; Progesterone

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; CASP3 PROTEIN, HUMAN; CASPASE; CASPASE 3; CRYSTAL VIOLET; HORMONE ANTAGONIST; INDOLE DERIVATIVE; MIFEPRISTONE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROGESTERONE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; FEMALE; FLUORESCENCE MICROSCOPY; HUMAN; IMMUNOBLOTTING; METABOLISM; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; CASPASE 3; CASPASES; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENTIAN VIOLET; HORMONE ANTAGONISTS; HUMANS; IMMUNOBLOTTING; INDOLES; MICROSCOPY, FLUORESCENCE; MIFEPRISTONE; OVARIAN NEOPLASMS; POLY(ADP-RIBOSE) POLYMERASES; PROGESTERONE; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 33746416773     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.4.743     Document Type: Article

References (43)

1. Risch HA: Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 90: 1774-1786, 1998.
2. Rose PG, Nerenstone S, Brady MF, et al: Secondary surgical cytoreduction for advanced ovarian carcinoma. N Engl J Med 351: 2489-2497, 2004.
3. Schneider HP and Birkhauser M: Does HRT modify risk of gynecological cancers? Int J Fertil Menopausal Stud 40 (suppl 1): 40-53, 1995.
4. Riman T, Nilsson S and Persson IR: Review of epidemiological evidence for reproductive and hormonal factors in relation to the risk of epithelial ovarian malignancies. Acta Obstet Gynecol Scand 83: 783-795, 2004. (Pubitemid 39179432)
5. Pike MC, Krailo MD, Henderson BE, Casagrande JT and Hoel DG: 'Hormonal' risk factors, 'breast tissue age' and the age-incidence of breast cancer. Nature 303: 767-770, 1983. (Pubitemid 13054488)
6. Konishi I, Kuroda H and Mandai M: Review: gonadotropins and development of ovarian cancer. Oncology 57 (suppl 2): 45-48, 1999. (Pubitemid 29494884)
7. Whittemore AS, Harris R and Itnyre J: Characteristics relating to ovarian cancer risk: collaborative analysis of 12 US case-control studies. IV. The pathogenesis of epithelial ovarian cancer. Collaborative Ovarian Cancer Group. Am J Epidemiol 136: 1212-1220, 1992. (Pubitemid 23026892)
8. Hankinson SE, Colditz GA, Hunter DJ, Spencer TL, Rosner B and Stampfer MJ: A quantitative assessment of oral contraceptive use and risk of ovarian cancer. Obstet Gynecol 80: 708-714, 1992.
9. Risch HA, Marrett LD and Howe GR: Parity, contraception, infertility and the risk of epithelial ovarian cancer. Am J Epidemiol 140: 585-597, 1994. (Pubitemid 24313016)
10. Bosetti C, Negri E, Trichopoulos D, et al: Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer 102: 262-265, 2002. (Pubitemid 35222295)
11. Wenham RM, Lancaster JM and Berchuck A: Molecular aspects of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 16: 483-497, 2002. (Pubitemid 41123403)
12. Arends MJ, Morris RG and Wyllie AH: Apoptosis. The role of the endonuclease. Am J Pathol 136: 593-608, 1990. (Pubitemid 20105927)
13. Cohen JJ: Apoptosis. Immunol Today 14: 126-130, 1993.
14. Yu S, Lee M, Shin S and Park J: Apoptosis induced by progesterone in human ovarian cancer cell line SNU-840. J Cell Biochem 82: 445-451, 2001. (Pubitemid 32729408)
15. Bu SZ, Yin DL, Ren XH, Jiang LZ, Wu ZJ, Gao QR and Pei G: Progesterone induces apoptosis and up-regulation of p53 expression in human ovarian carcinoma cell lines. Cancer 79: 1944-1950, 1997.
16. Kalli KR, Bradley SV, Fuchshuber S and Conover CA: Estrogen receptor-positive human epithelial ovarian carcinoma cells respond to the antitumor drug suramin with increased proliferation: possible insight into ER and epidermal growth factor signaling interactions in ovarian cancer. Gynecol Oncol 94: 705-712, 2004. (Pubitemid 39194464)
17. Lindgren PR, Cajander S, Backstrom T, Gustafsson JA, Makela S and Olofsson JI: Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 221: 97-104, 2004. (Pubitemid 38829727)
18. Sartor O and Figg WD: Mifepristone: antineoplastic studies. Clinical Obstet Gynecol 39: 498-505, 1996. (Pubitemid 26143727)
19. Schneider MR, Michna H, Nishino Y and El Etreby MF: Antitumor activity and mechanism of action of different antiprogestins in experimental breast cancer models. J Steroid Biochem Mol Biol 37: 783-787, 1990.
20. Matsuda Y, Kawamoto K, Kiya K, Kuriso K, Sugiyama K and Uozumi K: Antitumor effects of antiprogesterones on human meningioma cells in vitro and in vivo. J Neurosurg 80: 527-534, 1994. (Pubitemid 24073016)
21. Lin MF, Kawachi MH, Stallcup MR, Grunberg SM and Lin FF: Growth inhibition of androgen-insensitive human prostate carcinoma cells by a 19-norsteroid derivative agent, mifepristone. Prostate 26: 194-204, 1995.
22. Rose FV and Barnea ER: Response of human ovarian carcinoma cell lines to antiprogestin mifepristone. Oncogene 12: 999-1003, 1996. (Pubitemid 26104441)
23. Murdoch WJ and van Kirk EA: Oestradiol inhibits spontaneous and cisplatin-induced apoptosis in epithelial ovarian cancer cells: relationship to DNA repair capacity. Apoptosis 2: 478-484, 1997. (Pubitemid 127508259)
24. Hamilton TC, Young RC, McKoy WM, et al: Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 43: 5379-5389, 1983. (Pubitemid 14230154)
25. Andrews NC and Faller DV: A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res 19: 2499, 1991.
26. Treloar AE, Boynton RE, Behn BG and Brown BW: Variation of the human menstrual cycle through reproductive life. Int J Fertil 12: 77-126, 1967.
27. Feng YJ, Jin ZJ, Zhang XY, et al: A preliminary study of the inhibitory effects of medroxyprogesterone on human epithelial ovarian cancer. Chin J Obstet Gynecol 30: 93-95, 1995.
28. Syed V and Ho SM: Progesterone-induced apoptosis in immortalized normal and malignant human ovarian surface epithelial cells involves enhanced expression of FasL. Oncogene 22: 6883-6890, 2003. (Pubitemid 37386688)
29. Keith Bechtel M and Bonavida B: Inhibitory effects of 17beta-estradiol and progesterone on ovarian carcinoma cell proliferation: a potential role for inducible nitric oxide synthase. Gynecol Oncol 82: 127-138, 2001. (Pubitemid 32634965)
30. McDonnel AC and Murdoch WJ: High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cells: evidence for a receptor-independent non-genomic effect on the plasma membrane. J Steroid Biochem Mol Biol 78: 185-191, 2001. (Pubitemid 32879334)
31. Ho SM: Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1: 73, 2003.
32. Kerr JF, Wyllie AH and Currie AR: Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer 26: 239-257, 1972.
33. Schneider CC, Gibb RK, Taylor DD, Wan T and Gercel-Taylor C: Inhibition of endometrial cancer cell lines by mifepristone (RU 486). J Soc Gynecol Investig 5: 334-338, 1998. (Pubitemid 28525422)
34. Li DQ, Wang ZB, Bai J, Zhao J, Wang Y, Hu K and Du YH: Effects of mifepristone on proliferation of human gastric adenocarcinoma cell line SGC-7901 in vitro. World J Gastroenterol 10: 2628-2631, 2004. (Pubitemid 39214491)
35. Wang G, Shang HL, Xie Y, Xiao P, Li XJ, Lin TC and Li GY: Effects of mifepristone on the proliferation, apoptosis and cis-diamminedichloroplatinum sensitivity of cultured chemoresistant human ovarian cancer cells. Chin Med J (Engl) 118: 333-336, 2005. (Pubitemid 40309643)
36. Li Q, Li JJ, Zhao XB and Ji M: Study of effect of mifepristone on apoptosis of human ovarian cancer cell line 3AO. Zhonghua Fu Chan Ke Za Zhi 38: 625-628, 2003.
37. Thomas M and Monet JD: Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line. J Clin Endocrinol Metab 75: 865-870, 1992.
38. El Etreby MF, Liang Y and Lewis RW: Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture. Prostate 43: 31-42, 2000. (Pubitemid 30164241)
39. Qin TN and Wang LL: Enhanced sensitivity of ovarian cell line to cisplatin induced by mifepristone and its mechanism. Di Yi Jun Yi Da Xue Xue Bao 22: 344-346, 2002.
40. Peters MG, Vanzulli S, Elizalde PV, Charreau EH and Goin MM: Effects of antiprogestins RU486 and ZK98299 on the expression of cell cycle proteins of a medroxyprogesterone acetate (MPA)-induced murine mammary tumor. Oncol Rep 8: 445-449, 2001. (Pubitemid 33758110)
41. Pollett JB, Zhu YX, Gandhi S, et al: RU486-inducible retrovirus-mediated caspase-3 overexpression is cytotoxic to bcl-xL-expressing myeloma cells in vitro and in vivo. Mol Ther 8: 230-237, 2003. (Pubitemid 37062833)
42. Liu Y, Wang LL and Deng Y: Enhancement of antitumor effect of cisplatin against human ovarian carcinoma cells by mifepristone in vivo. Di Yi Jun Yi Da Xue Xue Bao 23: 242-244, 2003.
43. Rocereto TF, Saul HM, Aikins JA Jr and Paulson J: Phase II study of mifepristone (RU486) in refractory ovarian cancer. Gynecol Oncol 77: 429-432, 2000. (Pubitemid 30368562)